Geider takes reins at ICC Lowe Pace

Share this article:
Gregg Geider
Gregg Geider

Gregg Geider, who headed up the Januvia diabetes account while at Omnicom's Harrison & Star, has joined IPG's ICC Lowe Pace as its new managing director, effective this month. He replaces Margaret Anne Ingram, SVP, management supervisor, who moves to the role of new business director.

While this is Geider's first role helming an agency, he comes to the full-service shop after high-profile work for some well-known brands. Most recently he led the professional brief for Merck's Januvia diabetes pill, which H&S had picked up in an agency consolidation in 2012. For several years, he also led global messaging for AbbVie's autoimmune blockbuster Humira, also at NYC-based H&S.

“[Gregg's] used to bringing resources together, and that's what I want Pace clients to expect moving forward,” said Steve Viviano, CEO of ICC Lowe. 

“I'm uniquely positioned to look into…what our clients and brands need and leverage those resources as necessary,” said Geider.

ICC Lowe Pace is one of two US-based conflict shops in the ICC Lowe network, the other being ICC Lowe Trio. It was rebranded to ICC Lowe Pace three years ago along with the rest of the ICC shops after Interpublic Group, ICC's parent, allowed Viviano to take over and grow healthcare within the holding company's Lowe & Partners network. 

Geider adds to a deep bench at the agency, which touts its depth and senior-level talent, a growing client base, but with a smaller agency's touch.

“The positioning for the office is ‘the boutique with access to the larger resources of ICC Lowe,' and we think that will go a long way for us,” said Viviano, citing the shop's DTC work as well as high-science accounts. “Gregg's focus now is on existing clients and helping them solve their challenges.”

Share this article:

Next Article in News

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.